and B-cell receptor signaling inhibitors, consistent with mechanisms complementary to these agents. These experimental findings have translated to the clinic, where single-agent use displays durable ...

The identification of pathogenic mechanisms relevant to these patients ... Every year, roughly 700 people in Finland develop diffuse large B-cell lymphoma. The most common symptom is enlarged ...

Dr. Hosoya says, "Although a few case reports of laryngeal edema with tisa-cel treatment for B-cell lymphoma have appeared, the mechanism of this phenomenon is still unknown and no established ...

The following is a summary of “A real-world pharmacovigilance assessment and literature review of lymphoma development in ...

About a third of patients with diffuse large B cell lymphoma (DLBCL), a fast-growing ... has been working to understand the underlying mechanisms of the targeted chemotherapy venetoclax.

When your doctor talks to you about your B-cell lymphoma, they'll tell you what type you have. It's an important piece of info to get, because each type of this cancer acts differently and has its ...

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

DelveInsight’s Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...